Solid Biosciences Inc. SLDB
7.60 USD +0.43 (+6.00%)
At closeNov 11, 2026, 4:01 PM EST
7.60 0.00 0.00%
After hours · Nov 11, 4:01 PM ET
7.18 Day range 7.86
4.16 52-week range 11.45
- YTD
- +34.75%
- 1 year
- +67.77%
News
benzinga.com Circio Enters Research Collaboration With Solid Biosciences To Evaluate Combining CircVec Generation 5 Construct With POLARIS-101 AAV Capsid For Genetic Heart Disease Gene Therapy The collaboration will evaluate combining the circVec generation 5 construct into POLARIS-101TM to address major unmet medical needs in genetic heart diseaseSolid Biosciences´ proprietary,…
globenewswire.com Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference CHARLESTOWN, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for…
globenewswire.com Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference CHARLESTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for…
globenewswire.com Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates - Duchenne (SGT-003): SGT-003 has been generally well tolerated in the 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of November 3, 2026 -
benzinga.com Solid Biosciences Says European Commission Grants Orphan Designation To SGT-212 For Treatment Of Friedreich’s Ataxia - Obtaining Orphan designation from the European Commission reflects Solid’s commitment to the global development of SGT-212 for individuals living with Friedreich’s ataxia -- SGT-212 is a…
benzinga.com UBS Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $20 UBS analyst Joon Lee initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Price Target of $20.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 7.8% to $1.52 during Friday's after-market session. The market value of their outstanding shares is at $3.3 million. 20/20 Biolabs…
benzinga.com This Brinker Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Analysts initiated coverage: Neutral on MCD; Buy on MOVE and EAT; Outperform on SLDB; Equal-Weight on GOLF, with price targets announced.
benzinga.com RBC Capital Initiates Coverage On Solid Biosciences with Outperform Rating, Announces Price Target of $18 RBC Capital analyst Luca Issi initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Outperform rating and announces Price Target of $18.- benzinga.com HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $25 Price Target HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $25 price target.
benzinga.com Nvidia To Rally Around 146%? Here Are 10 Top Analyst Forecasts For Thursday Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised Nutanix target, Ascendiant raised PAVmed target, Cantor raised Okta target, Piper raised Veeva…- benzinga.com Cantor Fitzgerald Maintains Overweight on Solid Biosciences, Raises Price Target to $26 Cantor Fitzgerald analyst Kristen Kluska maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $16 to $26.
benzinga.com Truist Securities Maintains Buy on Solid Biosciences, Raises Price Target to $20 Truist Securities analyst Danielle Brill maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and raises the price target from $16 to $20.
benzinga.com Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading…- benzinga.com Solid Biosciences Q2 EPS $(0.38) Beats $(0.46) Estimate Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.46) by 17.39 percent. This is a 9.52 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ:HUMA) shares moved upwards by 5.45% to…
benzinga.com Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls after pricing public offering of $50M. Other stocks decline in pre-market.- benzinga.com HC Wainwright & Co. Maintains Buy on Solid Biosciences, Raises Price Target to $25 HC Wainwright & Co. analyst Arthur He maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and raises the price target from $20 to $25.
- benzinga.com Wedbush Reiterates Outperform on Solid Biosciences, Maintains $16 Price Target Wedbush analyst Laura Chico reiterates Solid Biosciences (NASDAQ:SLDB) with a Outperform and maintains $16 price target.
benzinga.com Wedbush Maintains Outperform on Solid Biosciences, Lowers Price Target to $16 Wedbush analyst Laura Chico maintains Solid Biosciences (NASDAQ:SLDB) with a Outperform and lowers the price target from $17 to $16.- benzinga.com Piper Sandler Maintains Overweight on Solid Biosciences, Raises Price Target to $18 Piper Sandler analyst Biren Amin maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $17 to $18.
- benzinga.com Solid Biosciences Q1 EPS $(0.52) Misses $(0.44) Estimate Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.44) by 18.18 percent. This is a 11.86 percent increase over losses of…
- benzinga.com Solid Biosciences Doses First Participant In Phase 3 IMPACT DUCHENNE Clinical Trial For SGT-003 In Duchenne Muscular Dystrophy - Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid's integrated, multi-trial development program designed to support registration and global…
- benzinga.com Solid Biosciences Says European Commission Grants Orphan Drug Designation To SGT-003 For Treatment Of Duchenne Muscular Dystrophy - Orphan drug designation from the European Commission underscores Solid's commitment to advance SGT-003 through a global development effort for individuals living with Duchenne muscular dystrophy -…
benzinga.com JP Morgan Maintains Overweight on Solid Biosciences, Raises Price Target to $12 JP Morgan analyst Anupam Rama maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $11 to $12.
benzinga.com HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $20 Price Target HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $20 price target.
benzinga.com This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday Wall Street analysts changed ratings on top stocks. For insights on changes, see analyst ratings page. RBRK stock: buy or not? Analysts weigh in.
benzinga.com Guggenheim Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $26 Guggenheim analyst Debjit Chattopadhyay initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Price Target of $26.- benzinga.com Solid Biosciences Q4 EPS $(0.53) Misses $(0.50) Estimate Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.50) by 5.79 percent. This is a 47 percent increase over losses of…
- benzinga.com Wedbush Maintains Outperform on Solid Biosciences, Raises Price Target to $17 Wedbush analyst Laura Chico maintains Solid Biosciences (NASDAQ:SLDB) with a Outperform and raises the price target from $14 to $17.
benzinga.com Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned Solid Biosciences stock fell 8% after new SGT-003 Duchenne trial data. Investors remain cautious despite promising results and FDA plans.- benzinga.com Solid Biosciences' SGT-003 Shows Robust Microdystrophin Expression, DAPC Restoration, Cardiac Function Improvements And Encouraging Safety Profile In 40 INSPIRE DUCHENNE Participants; Plans For Additional Meetings With The FDA In H1 2026 - 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date -- Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex…
- benzinga.com Wedbush Reiterates Outperform on Solid Biosciences, Maintains $14 Price Target Wedbush analyst Laura Chico reiterates Solid Biosciences (NASDAQ:SLDB) with a Outperform and maintains $14 price target.
benzinga.com What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capricor, Moderna, and raising hopes for smoother drug approvals.
benzinga.com Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer treatment data. Hims & Hers and Xenon Pharma jump over 40%.- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Marvell Technology, Day One Biopharmaceuticals, Samsara And Other Big Stocks Moving Higher On Friday Dow Jones falls 500 points on Friday, Marvell Technology shares jump 18.4%, other stocks recording gains include DAWN, BATL, RCAT, and SWBI.- benzinga.com Solid Biosciences To Raise ~$240M Via Private Placement, Closing Expected March 9 Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities…
- benzinga.com Solid Biosciences Presents SGT-003, Next-Gen Investigational Gene Therapy For Duchenne Muscular Dystrophy, And SGT-212, Dual-Route Investigational Gene Therapy For FA At 2026 MDA Clinical & Scientific Conference Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced presentations on SGT-003, its…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com 'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screenings' - HHS
benzinga.com Solid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst Analyst Gil Blum initiated coverage of Solid Biosciences with a Buy rating and $16 price target, citing emerging gene therapies.
benzinga.com This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
benzinga.com Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket 
benzinga.com Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.- benzinga.com 'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics